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Abstract 
 
Regenerative medicine is emerging as a new approach to the treatment of severe 
cardiovascular diseases that are resistant to conventional therapies. While the type of 
cell transplanted (e.g., pluripotent stem cells, bone marrow-derived stem cells, skeletal 
myoblasts, or cardiac stem cells) influences the outcome of stem cell transplantation, 
the method of transplantation is also important, as the efficiency of engraftment after 
simple needle injection is poor. Scaffold-free cell sheet transplantation technology is 
one of the most promising methods in this regard. Although the results of clinical trials 
of stem cell therapy have been marginal to date, further elucidation of the actual 
mechanisms of cardiac repair following cell therapy would enhance the potential for 
full-scale implementation of stem cell therapy. In addition to stem cell therapy, the 
field of cardiovascular regenerative medicine includes interspecific chimera technology, 
drug delivery systems using biodegradable materials, and gene therapy. Integration of 
these new modalities with conventional therapies will be important to realizing the 
goal of cardiovascular regenerative medicine tailored to the condition of each 
individual patient. Cardiovascular surgery would be an excellent means of carrying out 
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number of advanced cardiovascular patients. Herein, we review the recent basic and 
clinical research associated with the realization of regenerative medicine in the field of 
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Introduction 
 
Cardiovascular disease remains the leading cause of death worldwide. In Japan, over 
57,000 cardiovascular surgeries for treatment of advanced cardiovascular diseases are 
performed annually
1
. However, the surgical treatment of severe heart failure is limited 
by the shortage of donors for heart transplantation and by the risk for serious 
complications, such as infection or cerebral thrombosis, after the implantation of 
ventricular assist devices. This health problem has prompted research into new 
therapeutic approaches, including cardiac regeneration
2
. Numerous valuable outcomes 
over more than a decade of basic research are now on the horizon of translation to 
clinical application (“from bench to clinic”), and the expectations from society are 
considerable. The field of cardiovascular surgical research, as the practical setting of 
such translational research, is now gathering significant attention from basic researchers. 
The results of basic research must be proven by preclinical experiments in animal 
disease models that mimic human diseases before the techniques can be applied 
clinically, and cardiovascular surgeons, as experts in human surgical treatments, are 
therefore the personnel best-suited to make practical contributions to advancing 
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In this review, we introduce recent basic and clinical research related to the field of 
cardiovascular surgery, including the different therapeutic approaches to, drawbacks of, 




Acute ischemic injury and chronic cardiomyopathies lead to permanent loss of cardiac 
tissue and, consequently, heart failure. Cell transplantation is thought to be an ideal 
therapeutic method for replacing lost myocardium
3,4
. Of the available cell sources, stem 
cells are now widely preferred for research or clinical trials concerning cardiac cell 
therapy
2,5
. The discovery of various stem cell populations possessing cardiogenic 
potential and the subsequent development of methods to isolate and expand these cells 
have begun to shape the notion of restorative therapy. In spite of the great deal of 
knowledge gained through numerous basic research studies, significant barriers to true 
cardiac regeneration remain, and the field still lacks results sufficiently conclusive to 
support full-scale implementation of such therapies. Very few of the transplanted tissue 
stem cells seem to differentiate into mature cardiovascular cell types, suggesting that 
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favorable processes, including angiogenesis, prevention of apoptosis, and promotion of 
healing, in the injured myocardium rather than differentiating into renewed 
myocardium
2
. In this section, we introduce the present research achievements in stem 
cell therapy using various cell types, including clinical trials employing said cell sources, 
as well as the transplantation technologies that best support effective engraftment of the 
transplants. The characteristics of each stem cell population with respect to therapeutic 
potential are summarized in Table 1.  
 
Pluripotent stem cells 
Embryonic stem cells (ESCs) can be removed from the inner cell mass of the 
blastocyst and expanded in vitro practically indefinitely
6
. In culture, ESCs remain 
undifferentiated and pluripotent. When allowed to differentiate, ESCs can give rise to 
most somatic cell lineages
7
; their regenerative capacity is thus theoretically limitless. 
The advantages of these properties of ESC are especially significant for the heart as 
opposed to other organs, such as endocrine or sensory organs, as the heart functions as 
an assembly of many types of cells, including cardiomyocytes and others, and as 
numerous (>10
8
) heart-composing cells might be required to fully repair a damaged 
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other vascular cell types by culture as monolayers or embryoid bodies in various growth 
media
8-11
. These cells can then be transplanted into the heart. This approach to repairing 
cardiac tissue has been tested in preclinical studies with encouraging results
10,12
. In fact, 
of the various stem cell populations studied so far, ESCs have demonstrated perhaps the 
greatest capacity for cardiac cell differentiation and long-term cell survival
13
.  
To date, no human trials of the use of ESCs for cardiac repair have been attempted. 
There have been 3 main concerns regarding the use of ESC transplantation as a 
treatment modality. First, the differentiating cell mass contains cells from 3 germ layers, 
the ectoderm, mesoderm, and endoderm, and therefore possesses the capacity to 
differentiate along any or all of these lineages. This potential increases the risk of 
teratoma formation at the transplantation site. Although such teratomas are believed to 
be largely benign in vivo, some teratoma cells have been found to express markers 
similar to those found in malignant tumors
14
. We recently reported that the 
transplantation of cell sheets reassembled with defined mouse ESC-derived 
cardiovascular populations resulted in functional improvement in a rat sub-acute 
myocardial infarction (MI) model, and no tumors formed within the 3-month 
observation period after transplantation
12
. Transplantation of such fully differentiated 
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transplantation of differentiated cells have shown increased engraftment and functional 
improvement
10,13
. While no long-term studies assessing the real risk of teratoma 
formation have yet been performed, the theoretical concern remains an important 
obstacle. The second issue concerns immunity. ESCs have been reported to express 
specific human leukocyte antigen (HLA) subclasses
15
; this raises worries about graft 
rejection and might necessitate immunosuppression, which could increase the risk of 
surgical wound infection after cell transplantation surgery. Finally, the origin of ESCs 
has raised considerable ethical concerns and led to heated debates among scientists and 
the wider public.  
The discovery that reprogramming adult somatic cells with genes that confer ESC 
pluripotency generates ESC-like cells, called induced pluripotent stem cells (iPSCs), 
may resolve the ethical and immunogenic issues associated with the use of ESCs
16,17
. 
Mouse iPSCs can be differentiated into cardiovascular cell populations almost identical 
to those produced from mouse ESCs, indicating that the regenerative capacity of iPSCs 
is almost equal to that of ESCs
18
. Furthermore, a potent differentiation protocol based 
on high-density monolayer cultures and chemically defined factors, and modifications 
thereof, have been reported to produce cardiomyocytes from human iPS cells with an 
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cardiac regenerative therapy utilizing human iPS cells. Recently, methods for generating 
human iPS cell lines without genomic integration by using episomal vectors
20
 or human 
artificial chromosome vectors
21
 have been reported. These may reduce tumorigenesis 
due to mutations, which could otherwise limit the clinical application of iPSCs. Based 
on the results of these basic studies, iPSCs are currently thought to be one of the most 
promising sources of cells for cardiac regeneration. However, further careful 
exploration of the feasibility of this new therapeutic modality will be required before its 
clinical application.  
 
Bone marrow-derived stem cells 
There are various cell subsets within the bone marrow niche that possess stem cell 
properties; these include hematopoietic progenitor/stem cells, mesenchymal stem cells, 
and endothelial progenitor cells. Each of these cell populations has both advantages and 
disadvantages for use in cardiac regeneration (Table 1). Although the capacities of these 
cells to differentiate into cardiomyocytes are rather low compared with those of 
ESC/iPSCs, their potential for cardiac restoration has been confirmed in many 
preclinical studies.  
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cells) are a well characterized and abundant source of progenitor cells. A number of 
remarkable studies have shown that direct transplantation or mobilization from 
endogenous reservoirs of bone marrow-derived cells significantly improves cardiac 
function. Some of these studies actually demonstrated regeneration of contracting 
cardiomyocytes and vascular beds
22,23
. However, other investigations found limited or 
no differentiation of bone marrow cells into cardiovascular cell types
24
; this suggests a 
beneficial effect independent of direct tissue regeneration, such as neovascularization 
due to paracrine effects. The observed improvements in cardiac function prompted a 
number of clinical trials using autologous bone marrow cells to treat patients with heart 
failure or MI. These studies used circulating hematopoietic progenitor cells, or bone 
marrow mononuclear cells (MNCs), which also contain hematopoietic stem cells. While 
the results of small early studies were encouraging, larger, randomized, 
placebo-controlled and blinded studies have shown mixed results
25,26
. The results of the 
REPAIR-AMI trial (the largest of the randomized, placebo-controlled trials) were 
positive in that left ventricular function improved and the combined clinical endpoint of 
death, MI, or revascularization within 2 years was reduced
27
. In contrast to the improved 
left ventricular function found by the REPAIR-AMI trial, a recent, randomized, 
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marrow MNCs were transplanted into patients with MI 2–3 weeks after successful 
percutaneous coronary intervention showed no beneficial effect on left ventricular 
ejection fraction (LVEF)
28
. These apparently conflicting results may be attributable to 
the cell preparation or the timing of cell administration. Further large-scale trials are 
clearly necessary to assess the role of infused bone marrow cells in cardiac repair in 
order to improve the therapeutic efficacy of this promising technique.  
Mesenchymal stem cells (MSCs) are a subset of stem cells found in the stroma of the 
bone marrow that can differentiate into osteoblasts, chondrocytes, and adipocytes
29
 and 
also into small numbers of cardiomyocytes
30
. MSCs are thought to be either less 
immunogenic than other lines
31
 or inherently immunomodulatory
32
, alleviating the need 
for immunosuppression or autologous therapy. Preclinical studies of transplantation of 
MSCs into post-infarct animals demonstrated improved left ventricular function, 
reduced infarct size, and increased survival rate
30,31,33
. A clinical study of MSCs in 
patients with MI demonstrated improvement of left ventricular function
34
. The 
disadvantage of MSCs for this clinical application is their broad differentiation capacity. 
MSC populations remain significantly heterogeneous and are therefore less predictable 
after transplantation. Some studies have indicated that transplanted MSCs had 
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Another bone marrow cell subset is the endothelial progenitor cells (EPCs). In the past, 
angiogenesis was thought to occur exclusively though the proliferation of mature 
endothelial cells at injury sites. This concept has changed with the discovery that bone 
marrow-derived EPCs reach injury sites and incorporate into the microvasculature 
(vasculogenesis)
36
. This finding drastically altered our understanding of vascular growth 
and became a new therapeutic approach. EPCs can be identified by their ability to 
acquire endothelial cell characteristics, i.e., the expression of cell surface makers such 
as cluster of differentiation molecule 133 (CD133), CD34, the vascular endothelial 
growth factor receptor 2 kinase (VEGFR-2; also designed as KDR), and vascular 





 cells are the most widely recognized and utilized
37
. EPCs are mobilized from 
the bone marrow during states of injury, such as trauma, MI, or cancer
38-40
. The research 
into their use began with attempts to enhance their mobilization or incorporate EPCs 
directly into the vasculature of injured sites. VEGF, granulocyte colony stimulating 
factor (G-CSF), and statins (3-hydroxy-3-methylglutaryl coenzyme-A reductase 
inhibitors) have been reported to increase the mobilization of EPCs from the bone 
marrow
41-43
. Preclinical studies of the use of EPCs to treat experimental hind-limb 
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salvage
36
. Furthermore, injection of EPCs into infarcted myocardium improved left 
ventricular function
44
. The results of a randomized multicenter clinical trial in patients 
with acute ischemia (REGENT trial) showed no significant improvement in left 
ventricular function after treatment with EPCs. However, there was a trend in favor of 
EPC therapy in the patients with the most severely impaired left ventricular function 
and in those with longer delays between the onset of symptoms and revascularization
45
. 
EPCs have already been used in the field of interventional cardiology. Drug-eluting 
stents (impregnated with various chemicals that inhibit neointimal thickening) reduce 
the restenosis rate but increase the risk of in-stent thrombosis, a potentially fatal event. 
GENOUS stents are coated with anti-CD34 antibodies, which work to trap circulating 
EPCs and augment the process of luminal endothelialization; this may prevent 
restenosis
46
. A prospective study showed that implantation of the EPC-capture stent is 
safe and effective, with satisfactory immediate results and mid-term outcomes and no 
evidence of stent thrombosis
47
. However, EPCs have several disadvantages as a 
therapeutic material. First, this cell population is heterogeneous: EPCs circulating in the 
peripheral blood span the full range of differentiation from angioblasts to mature 
endothelial cells. Second, the stem cell pool of EPCs is quite limited, and ex vivo 
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of a significant injury or ischemic event
48
. Finally, the circulating pool of EPCs is 
reduced in patients with such common comorbidities of cardiac ischemic disease as 
diabetes mellitus, hypertension, and hypercholesterolemia
49
. Although further research 
is required to overcome these problems and to enhance the therapeutic efficiency of 




In adult skeletal muscle, a stem cell population called “satellite cells” exists beneath the 
basal membrane of muscle tissue, where they lie dormant until stimulated by muscle 
injury to proliferate
50
. Skeletal myoblasts (SMs) are derived from the satellite cells. 
SMs have been considered an attractive source for cardiac repair for several reasons. 
First, these cells are further differentiated than ESCs and therefore less prone to 
teratoma formation. Second, they can be harvested from the host, expanded ex vivo, and 
autologously re-transplanted, thus avoiding the need for immunosuppression
51
. Third, 
SMs are resistant to ischemia, an obstacle to the function of stem cells in injured 
myocardium, and are therefore especially appropriate for cardiac repair
52
. Finally, SMs 
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transplantation experiments in animal cardiac disease models produced improved left 
ventricular function and decreased remodeling
51,52,54,55
. However, skeletal myoblasts do 
not fully differentiate into cardiomyocytes in vivo after transplantation, and the 
myotubules generated do not operate in synchrony with the surrounding myocardium
55
, 
possibly due to a lack of connexin activity and electrical coupling with the surrounding 
myocardial cells. However, the improvement in left ventricular function in animal 
models prompted a series of clinical investigations. Early clinical studies were aimed at 
assessing the feasibility and safety of SM implantation
52,56,57
. Although these studies 
proved the therapy feasible and showed that SMs survive in the heart, only marginal 
benefit was recognized. Larger scale clinical trials were undertaken to assess the benefit 
of myoblast therapy. The most notable to date was the Myoblast Autologous Grafting in 
Ischemic Cardiomyopathy (MAGIC) trial, which randomized patients to receive 
injection of either SMs or culture medium. The results of this trial have been 
disappointing in that no significant benefit of SM transplantation has been observed
58
. 
Further clinical studies are ongoing and may show different results. Several barriers to 
the use of SMs still remain. The first limitation is the arrhythmogenic potential of the 
engrafted SMs. The MAGIC trial showed a higher number of arrhythmic events in the 
myoblast-treated patients
58
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of SMs to host cardiomyocytes increases when the SMs are induced to overexpress 
connexin 43, indicating that their arrhythmogenicity may be a surmountable obstacle
59
. 
The second limitation is the relatively poor engraftment of the injected cells into the 
host myocardium. Cellular mortality of over 90% within the first few days after 
injection has been reported in mice
60
. Some studies in humans have shown similarly 
high rates of cell death, with only scarce surviving cells
52
. Clinical research on 
autologous myoblast-sheet transplantation for treatment of severe heart failure is now 
ongoing in Japan
61
. As the cell sheet transplantation method is thought to improve the 
survival of the transplants over needle injection (mentioned below), this strategy is a 
promising means of resolving the survival problem, and better clinical outcomes would 
be expected. The third limitation of SM use is that the engrafted cells differentiate into 
myotubules rather than cardiomyocytes and therefore do not constitute a true 
regenerative therapy.  
 
Cardiac stem cells 
The modest (rather unsatisfactory) functional effects of the transplantation of bone 
marrow cells or SMs in human studies have stimulated further research into the natural 
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been considered a post-mitotic organ, and mature cardiomyocytes withdraw from the 
proliferative cell cycle. However, contradictory data have accumulated, as 
cardiomyocyte proliferation and cell cycling have been observed under pathological 
conditions such as hypertension or MI
62,63
 and even in the healthy heart
64
. Moreover, 
estimates of the death rates of adult cardiomyocytes suggested the existence of a pool of 
cardiac progenitor cells
65
. This evidence prompted a search for such resident cardiac 
cells. Several different cell populations with stem cell characteristics were subsequently 
discovered in the adult heart. The first cell population with stem cell properties is called 
the side population (SP); these cells have also been identified in various other organs, 
including bone marrow, skeletal muscle, and adipose tissue
66
. Isolated cardiac SP cells 
can differentiate into cardiomyocytes, endothelial cells, or smooth muscle cells, 
suggesting that they represent cardiac and vascular progenitor cells
67
. The second 
putative resident progenitor population constitutes cells expressing the stem cell factor 
receptor c-Kit (also designed as CD117), which are located in small clusters within the 
adult heart. c-Kit
+
 cells have regenerative potential after transplantation and give rise to 
cardiomyocytes, endothelial cells, and smooth muscle cells. c-Kit
+
 cell transplantation 
after ischemic injury significantly improves cardiac function
68
. The third cell type in the 
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Sca-1
+
 cells home to infarcted myocardium and differentiate into cardiomyocytes 
around the injured area
69
. Finally, enzymatic digestion of heart tissue obtained via 
endomyocardial biopsy yields round cardiac progenitor cells that form so-called 
cardiospheres in suspension
70
. Cardiosphere-derived cells (CDCs) can also differentiate 
into cardiomyocytes, endothelial cells, and smooth muscle cells and exhibit remarkable 
capacities for proliferation and differentiation
70
. Once isolated, this cell population can 
be induced to differentiate into spontaneously contracting aggregates of cardiomyocytes 
that can then be transplanted into injured myocardium
71
. The injection of CDCs has 
produced functional improvement in preclinical studies
71
. Small numbers of CDCs have 
been observed to integrate into the injured myocardium, but this extent of cardiac tissue 
regeneration is insufficient to explain the functional improvement.  
Cardiac stem cells appear to exist in specialized niches that support the growth and 
maintenance of the stem cell pool
72
. Putative niches have been thought to be localized 
throughout the myocardium
68
. However, there is recent evidence that the adult heart 
contains a resident stem cell population that originates from the epicardium and has the 
potential to differentiate into cardiomyocytes after MI
73
. Although the different cardiac 
stem cell pools are small relative to the number of mature resident cardiomyocytes, they 
are believed to be the source of the new cells in damaged myocardium
74
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whether the various cardiac stem cells are distinct types or represent different stages of a 
single cell lineage. Furthermore, the cardiac stem cell pool appears to diminish with age, 
possibly contributing to the poor efficiency of regeneration in elderly people
74
. This 
highlights the need to discover how to rejuvenate this senescent stem cell population, as 
it is largely the elderly who suffer increased mortality from cardiac ischemia.  
Several phase-1 clinical trials using cardiac stem cells have been performed to date
75
. 
The CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction 
(CADUCEUS) study was a proof-of-principle study of intracoronary delivery of CDCs 
in patients with recent MI and left ventricular dysfunction
76
. In CADUCEUS, patients 
underwent endomyocardial biopsy sampling about 4 weeks after MI to generate 
autologous CDCs that were subsequently injected into the coronary artery. The rates of 
serious adverse effects and arrhythmias did not differ between patients in the CDC 
group and controls receiving conventional medical therapy. MRI analysis of patients 
treated with CDCs showed reduced scar mass and increased viable heart mass and 
regional contractility. However, changes in end-diastolic volume, end-systolic volume, 
and LVEF 6 months after transplantation did not differ between the groups. The Stem 
Cell Infusion in Patients with Ischemic cardiOmyopathy (SCIPIO) trial was performed 
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bypass grafting (CABG). Intracoronary administration of autologous c-Kit
+
 cardiac 
stem cells about 4 months after surgery improved LVEF, and no adverse effects related 
to cell administration were reported
77
. In Japan, the results of the AutoLogous Human 
CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA) trial, 
which tested combined therapy with autologous CDC transplantation and topical 
administration of basic fibroblast growth factor (bFGF), are now under evaluation
78
. 
Further investigations incorporating larger numbers of patients, longer follow-up times, 
and a true placebo arm will be needed to confirm the safety and efficacy of cardiac stem 
cell therapy.  
 
Effective cell delivery: beyond needle injection 
The results of this research have led to the conclusion that stem cells may be beneficial 
in the treated hearts but act primarily through paracrine mechanisms rather than through 
direct differentiation as initially expected. However, the low rates of grafted cell 
survival and engraftment diminish their potential and are serious technical limitations of 
stem cell therapy
79
. Over 70% of injected cells have been reported to die progressively 
during the first 48 hours after needle injection due to the hypoxic, inflammatory, and/or 
fibrotic environment
80
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directly injected into the beating myocardium remain shortly after the injection due to 
massive mechanical loss
81
. Therefore, new strategies such as combining the cells with 
bioengineering techniques have been developed and are the subjects of intense research, 
and early results suggest that these new strategies may improve the efficiency of stem 
cell therapies. Initial experiments were performed by combining the cells with injectable 
biomaterials such as collagen, fibrin, or gelatin. Matrigel and other factors that provide a 
favorable environment rich in cytokines and growth factors were also tested. In general, 
these early studies showed increased survival of the transplanted cells and greater 
improvements in the cardiac function of the treated hearts
82
. However, these approaches 
did not assure complete cell retention or adequate distribution of the grafted cells. New 
techniques such as the creation of microtissues, i.e., cell sheets or patches, are now 
being developed in order to enhance both cell survival and the homogeneous and 
organized distribution of the cells
83
. 
Cellular patches are created by using biomaterials that act as delivery platforms or 
scaffolds for the cells, assuring their engraftment and interaction with the tissue. One 
class of materials used is hydrogel/extracellular matrix-based matrices, in which the 
cells are embedded in a soluble hydrogel matrix that condenses in response to a 
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Patches of MSCs entrapped in a collagen-I matrix have been created and implanted into 
infarcted rat hearts, where they increased cell engraftment and functional improvement; 
these results appear to have been due to potentiation of the trophic effect of the MSCs 
by their increased survival in the tissue in the patch format
84
. Three-dimensional 
contractile loops of mixed collagen and neonatal cardiomyocytes, a more-sophisticated 
approach, have been successfully created. Implantation of these loops could support the 
contractile function of damaged heart
85
.  
Another promising approach is the creation of cell sheets with no scaffold support. 
This approach would avoid inflammatory reactions against the biomaterials constituting 
the scaffolds. Scaffold-free sheets have been constructed using culture dishes covalently 
grafted with the temperature-responsive polymer poly (N-isopropylacrylamide) 
(PIPAAm), which enables the preparation of cell sheets without enzymatic digestion
86
. 
The beneficial potential of this technique has been demonstrated by the transplantation 
of monolayers of adipose tissue-derived MSCs
33
 or triple-layer cardiac tissue sheets 
bioengineered with ESC-derived defined cardiac cell populations (our recent report)
12
 
into infarcted hearts. Both methods demonstrated increased tissue neovascularization 
and positive attenuation of heart remodeling, resulting in improved cardiac function. 
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more effective cardiac regeneration. However, no evidence of the reinforcement of 
contraction by the physical integration of the cell sheet and host myocardium was 
reported to date. To realize that, more increased survival of cell sheets would be 
essential, and supplemental strategies together with current cell sheet transplantation, 
such as vascularization of cell sheet, might be promising
12
.  
Transplantation of in-vitro-created 3D cardiospheres has recently been shown to 
improve both engraftment of cardiac progenitors and their in-vivo differentiation 
towards cardiac and vascular cells
87
. De-cellularized tissues have also been explored as 





have also been used to support cell types such as mesenchymal cells in order to enhance 
their paracrine effects. However, obtaining sufficient cardiac cells with no 
immunological risk and creating patches/organs that mimic the structure and function of 
the heart remain challenging.  
 
Future directions for cardiac cell therapy 
In spite of the knowledge described above, the application of stem cells have been 
much less studied in chronically than in acutely infarcted hearts
90
. Indeed, stem cell 
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Although the inhibition of tissue degeneration in the acute stage of the disease through 
paracrine effects such as angiogenesis is a main goal of cell therapy, the implementation 
of this strategy in hearts with chronic MI, in which the inflammation has receded and 
the angiogenic processes mostly ended, could also have therapeutic effects such as 
avoiding progression toward heart failure, reducing fibrosis, or regenerating the 
myocardium as a new contractile muscle mass. To date, cell therapy for chronic MI has 
been effective in both small and large animal models
33,55,89
. However, despite some 
exceptions, the effect on cardiac contractility is indirect rather than through true cardiac 
regeneration.  
One future direction is the combination of stem cell therapy and conventional surgical 
procedures. Concomitant CABG and stem cell administration has been studied in 
patients with chronic myocardial ischemia, but the results were too marginal to justify 
full-scale therapeutic implementation
58,77
. We have previously reported that combined 
rat fetal cardiomyocyte injection and plication of left ventricular aneurysm resulted in 
sufficient functional improvement in a rat chronic MI model
4
. The combination of cell 
therapy and various surgical procedures other than CABG, such as left ventricular 
reconstruction or mitral repair for ischemic mitral insufficiency, might be a promising 
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severe chronic heart failure who are ineligible for heart transplantation.  
Another direction of future research is the further elucidation of the mechanisms of 
cardiac repair through cell therapy. Previous studies of stem cell therapy relied on 
injections of heterogeneous cell populations, which limited the insights they could 
provide into the cellular and molecular behaviors and mechanisms of action of 
transplanted cells. An understanding of the roles of each cell population as well as the 
various complex intercellular interactions in the heterogeneous populations transplanted 
would be a breakthrough in the improvement of cardiac cell therapy. Utilizing the 
mouse ES cell differentiation system to obtain defined cardiovascular populations, we 
recently found a major cellular mechanism, that is, cardiomyocytes are essential for 
sufficient cardiac restoration after sub-acute MI mainly through angiogenesis
12
. This 
approach to the elucidation of the regenerative mechanisms could be especially 
important in the context of chronic MI.  
The last direction of future research that we introduce in this section is the 
“bioartificial heart.” Replacing the injured area with a cardiac sheet or patch might be 
useful when a relatively small area of the heart is affected. However, this approach 
would not suffice when the heart has become nonfunctional and organ transplantation is 
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theoretically avoid the problems of both organ transplants, such as donor shortages and 
immune rejection, and those of mechanical hearts, such as thromboembolism formation. 
In-vitro heart “reconstruction” using decellularized cadaveric hearts has been 
demonstrated to be feasible. It is possible to re-vascularize and re-muscularize a heart 
“skeleton” of which only the extracellular matrix has been preserved to create a new 
heart. Cardiomyocytes and endothelial and fibroblastic cells are perfused using a 
bioreactor, which provides a pulsatile flow and pacing that mimics physiological 
conditions. Surprisingly, such newly formed hearts can contract spontaneously
91
. Of 
course, many issues, such as methods for isolating a sufficient volume of cardiovascular 
cell populations without the risk of immune rejection (in this regard, iPS cells would be 
the ideal cell source) and preventing fatal arrhythmias, remain to be resolved before 
these bioartificial organs are developed to the point of clinical use. In any case, the 
demonstration of the possibility of creating such organs represents a great step forward 
in the treatment of cardiac diseases.  
 
Other research related to cardiovascular regeneration 
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There are many promising approaches to cardiac regeneration besides the cell 
therapies discussed above. The generation of human hearts from other animals by using 
interspecific chimera technology with blastocyst complementation is one such approach. 
The injection of rat wild-type iPSCs into Pdx1
-/-
 (pancreatogenesis-disabled) mouse 





. This result indicates that organs derived from donor iPSCs 
can be generated in vivo in a xenogenic environment. The development of this 
technology for the generation of human hearts within size-matched animals, such as 
pigs, is ongoing in Japan (“NAKAUCHI Stem Cell and Organ Regeneration” project93).  
However, several problems remain to be overcome. The first of these concerns 
xenotransplantation. As the vessels (including the aorta and other large vessels), blood 
cells, nervous system, and other associated tissues would be derived from animals, 
while the organ itself would be of human origin, the transplantation of these chimeric 
organs into humans would be partial xenotransplantation rather than full 
allo/auto-transplantation. The generation of animals with genetically human blood 
vessels and nervous systems would be one solution to the potential for immunological 
rejection of xenotransplanted organs. The second problem is that in the abovementioned 
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and tissues, including the brain and gonads
92
. Without proper control of the 
differentiation of iPSCs, the generation of human organs in livestock animals will pose 
ethical issues. One approach to addressing this problem is the use of lineage-committed 
stem or progenitor cells in place of iPSCs. The introduction of such cells into an 
appropriate microenvironment at the appropriate developmental time point might allow 
restriction of differentiation to a particular organ.  
 
Biomaterials for efficient drug delivery 
The technology for realizing the beneficial effects of cell therapy must be further 
advanced before it can attain its full potential. The combination of cell therapy and local 
administration of proteins that induce paracrine effects such as angiogenesis is one 
possible method of enhancing the therapeutic potential of cell therapy. Tabata et al. 
have developed a system for sustained release of angiogenic cytokines, such as bFGF, 
from a biodegradable material, gelatin hydrogel; this system enables us to control the 
release of cytokines over the periods required for efficient clinical outcomes
94
. The 
addition of such sustained release of bFGF enhanced the functional benefit of the 
transplantation of CDCs in a porcine MI model
71
 and is being used in the ongoing 
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In addition to its use in cardiac regeneration, the sustained-release system is also 
applicable to the treatment of critical limb ischemia. We found that the sustained release 
of bFGF improved the resolution of foot ulcers or other clinical symptoms in patients 
with severe limb ischemia in an initial phase 1–2a study95, and an advanced clinical trial 
is now ongoing. Drug delivery systems using biodegradable biomaterials could thus be 
a promising strategy for the advancement of cardiovascular regeneration.  
 
Gene therapy 
Another avenue of regenerative medicine is gene therapy, which is emerging as a 
potential treatment option in patients suffering from a wide spectrum of cardiovascular 
diseases, including coronary artery disease, peripheral vascular disease, vein graft 
failure, and in-stent restenosis
96
. Gene therapy, which is the direct introduction of 
transgenes into the vasculature or myocardium, may contribute to controlling the 
symptoms of cardiovascular disease and may also be able to reverse the pathological 
processes involved. However, before these objectives can be achieved, 3 goals must be 
accomplished: suitable vectors must be generated, a suitable gene or group of genes 
must be identified, and an appropriate delivery system must be developed. The optimal 
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Gene therapy to induce calcium upregulation in patients with advanced heart failure 
was recently attempted. The Calcium Upregulation by Percutaneous Administration of 
Gene Therapy in Cardiac Disease (CUPID), a phase-2 trial, decreased the frequency of 
cardiovascular events in the patient group, who received intracoronary administration of 





(miRNAs), which are small, non-coding RNAs that regulate gene expression in a 
sequence-dependent manner, are also being investigated as a new modality of gene 
therapy for ischemic heart disease or vascular diseases
98
. 
In 2010, Ieda et al. reported that a combination of 3 developmental transcription 
factors (Gata4, Mef2c, and Tbx5) rapidly, efficiently, and directly reprogrammed 
postnatal cardiac or dermal fibroblasts into differentiated cardiomyocyte-like cells in 
vitro (direct reprogramming)
99
. This technology was recently applied to an in-vivo 
mouse MI model in which the 3 genes were delivered by a retroviral vector, resulting in 
the direct reprogramming of cardiac fibroblasts within the infarction site into 
cardiomyocyte-like cells and the attenuation of cardiac dysfunction
100
. Therefore, 
despite concerns over the ethics and safety of gene therapy (the latter related to the 
potential unexpected side effects of genomic integration), it is a promising segment of 






































































Herein, we introduced the status quo and future directions of stem cell therapy for 
treatment of cardiac disease and, more briefly, other approaches to cardiac regenerative 
research. We emphasize that we should not discuss which of these therapeutic 
modalities is to be preferred but rather consider them as components of an integrated 
medicine that would, as the summation of the new therapies introduced in this review 
and others that were not discussed, constitute a step towards the realization of cardiac 
regenerative therapy as a realistic option. In this context, the power of cardiovascular 
surgery as the integrator of basic research and clinical practice is virtually 
immeasurable.  
Although much more work remains to be done, cardiac regenerative medicine, in 
conjunction with current treatment modalities, may help to further reduce the mortality 
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Table Legends 
 
Table 1:  


































































Stem cell type Origin Advantages Disadvantages Clinical trials 
Pluripotent stem cells 
Embryonic stem cells (ESCs) Inner cell mass of the 
preimplantation blastocyst 
Theoretically unlimited self-renewal 
capacity; pluripotency 
Ethical considerations; teratoma 
formation; graft-versus-host disease 
None 
Induced pluripotent stem cells Most somatic cells (e.g., 
skin fibroblasts) 
Same advantages as ESCs; free from 
ethical/immunological issues 
Potential teratoma formation None 
Bone-marrow derived stem cells 
Hematopoietic stem cells 
(circulating progenitor cells, bone 
marrow mononuclear cells) 
Bone marrow, peripheral 
blood  
Easy to isolate; safe and feasible to 
transplant 
Limited potential for differentiation 




Mesenchymal stem cells Bone marrow (adherent 
cells), adipose tissue 
Easy to isolate and expand in culture; 
less immunogenic than other lines; 
multipotent 
Great heterogeneity; heterotopic 
differentiation (e.g., ossification) 
Report from Chen et al. 
(China)34 
Endothelial progenitor cells Bone marrow, peripheral 
blood 
Mobilized from bone marrow or 
present in peripheral blood; important 
in vasculogenesis 
Heterogeneity; small populations; 
reduced in individuals with 
cardiovascular comorbidities 
REGENT45  
Skeletal myoblasts Mature skeletal muscle  Extensive scalability; resistance to 
ischemia; multipotent; no teratoma 
formation 
Potential for arrhythmias; lack of 
cardiomyocyte differentiation  
MAGIC58, CAuSMIC57 
Cardiac stem cells Special niches in the 
myocardium  
Resident in therecipient heart; robust 
cardiovascular differentiation potential; 
reduced tumor formation 
Stem cell pool appears to undergo 




Table 1: Characteristics of stem cell populations used for cardiac cell transplantation therapy.  
Table
